Under Portugal's new regime, people found guilty of possessing small amounts of drugs are sent to a panel consisting of a psychologist, social worker and legal adviser for appropriate treatment (which may be refused without criminal punishment), instead of jail. The question is, does the new policy work?
The International AIDS Society letter to the CND calls for the inclusion of evidence-based support for harm reduction, and for essential medicines for OST and palliative care into the global frameworks for control of narcotic drugs.
In this letter, the Special Rapporteurs are deeply critical of the failure of the draft UN political declaration and annex to give any mention of harm reduction.
This proceedings document provides the reader with a summary of what happened at the 52nd session of the CND and its High Level Segment and offers an analysis of some of the key discussions and debates.
Political representatives from over 130 countries gathered at a United Nations high level meeting in Vienna on 11th/12th March 2009 to conclude a 2-year long review of progress achieved within the global drug control system.
The accounts below, drawn from published literature and from those who have passed through treatment in Asia and the former Soviet Union, detail the range of abuses practiced in the name of drug dependence treatment, and suggest the need for reform on grounds of health and human rights.
This analysis demonstrates that a move to legally regulated drug supply would deliver substantial benefits to the Treasury and wider community, even in the highly unlikely event of a substantial increase in use.
The Political Declaration adopted on the 12th March 2009 at the High Level Segment of the 52nd Session of the CND is a framework and a set of priorities for the next 10 years of international drug policy. IDPC and its members have followed with interest the process for reviewing progress against the objectives set at the General Assembly Special Session on Drugs in 1998 - namely, to eradicate or significantly reduce the production of, and demand for, the non-medical use of controlled drugs.
